Wanbury Ltd (WANBURY) — shareholding pattern, promoter holding, financials and share price
About Wanbury Ltd (WANBURY)
Wanbury Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as WANBURY and on the BSE under scrip code 524212. Its ISIN is INE107F01022.
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research [1]
Wanbury Limited specializes in the pharmaceutical sector, focusing on Active Pharmaceutical Ingredients (APIs) and formulations. It holds a significant global market share in products such as Metformin and Sertraline, establishing robust leadership in these key therapeutic categories.
The company has successfully undergone an operational and financial turnaround over the last two years, transitioning towards growth momentum and de-risked financial structures, with a notable reduction in debt levels and borrowing costs.
Listed peers in Pharmaceuticals: Bajaj Healthcare Ltd, Themis Medicare Ltd, Bharat Parenterals Ltd, Kopran Ltd, Shree Ganesh Remedies Ltd, Hexagon Nutrition Ltd.
Valuation & Returns
10 Jul 2026At ₹300 a share on 10 Jul 2026, Wanbury Ltd (WANBURY) was valued at a price-to-earnings ratio of 24.38x against an industry P/E of 36.41x and a price-to-book of 17.68x on a book value of ₹16.96 per share as of Mar 2025. Solomo computes return on equity of 72.53% and return on capital employed of 33.46% from filed results. Earnings ratios use consolidated results for the twelve months Sep 2024 to Jun 2025.
- P/E
- 24.38x
- Industry P/E
- 36.41x
- P/B
- 17.68x
- EPS (TTM)
- ₹12.3
- Book value / share
- ₹16.96
- ROE
- 72.53%
- ROCE
- 33.46%
- ROA
- 10.39%
- Debt / equity
- 2.98x
- Dividend yield
- 0%
- EBITDA margin
- 14.72%
- 52-week range
- ₹162 – ₹316.6
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Wanbury Ltd (WANBURY) reported revenue of ₹600 crore, net profit of ₹31 crore and earnings per share of ₹9.32. That compares with revenue of ₹557 crore and net profit of ₹56 crore in Mar 2024. Figures are consolidated, as filed with the exchanges.
In the quarter ended Jun 2025, revenue was ₹163 crore and net profit ₹13 crore (consolidated).
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 392 | 511 | 485 | 557 | 600 |
| Net profit (₹ cr) | -13 | 81 | -10 | 56 | 31 |
| EPS (₹) | -5.04 | 24.94 | -3.18 | 17.09 | 9.32 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 3.66% | 10.29% | 5.46% | 3.77% |
| Profit growth | - | -13.88% | -27.91% | -45.44% |
| Stock price CAGR | 24% | 32% | 91% | 28% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 43.02% of Wanbury Ltd (WANBURY) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.89% and domestic institutional investors (DII) hold 0.06%. Promoters have pledged 62.2% of their holding. Market capitalisation was ₹1,048 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2002.
Largest disclosed public shareholders in Jun 2026: SURESH BHATIA 3.11%, AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED 2.07%, ZAKI ABBAS NASSER 1.76%, SHARMIN NASSER 1.33%, BASAVA SANKARARAO KOLLI 1.16%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 43.02% | 62.2% | 0.89% | 0.06% | 56.98% |
| Mar 2026 | 43.02% | 62.2% | 0.59% | 0% | 56.98% |
| Dec 2025 | 43.07% | 62.2% | 0.72% | 0% | 56.93% |
| Sep 2025 | 43.09% | 62.2% | 0.82% | 0% | 56.91% |
| Jun 2025 | 39.63% | 76.7% | 1.59% | 0% | 60.37% |
| Mar 2025 | 39.76% | 76.7% | 1.55% | 0% | 60.24% |
| Dec 2024 | 39.76% | 76.7% | 0.84% | 0% | 60.24% |
| Sep 2024 | 39.77% | 76.7% | 1.02% | 0% | 60.23% |